Related Experiment Videos
Mitomycin C: phase I study of a constant infusion ambulatory treatment schedule
Abstract:
Thirty patients received mitomycin C by constant infusion for 5 consecutive days (16 patients ) or for extended period by an ambulatory infusion pump (Cor-Med model) for 9 to 30 days (14 patients). The short-term 5-day infusions were delivered at dose rates of 2, 3, 4, 5 and 6 mg/m2/d with a cumulative dose of 15-50 mg. The protracted infusions were delivered at dose rates of 0.75-3 mg/m2/d with a cumulative dose of 21.6-65.2 mg. Marrow suppression was dose-limiting and occurred in 5/6 evaluable patients receiving more than 30 mg in the short-term infusion schedule and 8/10 evaluable patients receiving more than 20 mg in the protracted infusion schedule. The characteristics of the marrow suppression are that: a) thrombocytopenia precedes or is observed without concomitant leukopenia and b) the nadir day is delayed (WBC day 42, platelet day 36). Mitomycin C delivered by constant infusion leads to dose-limiting marrow toxicity at 20 to 30 mg cumulative dose depending upon the dose rate and duration of treatment. For short-term 5-day therapy, 3 mg/m2/d and for protracted therapy (up to 30 d) 0.75 mg/m2/d are the recommended dose rates for the constant infusion schedule.
Insights
Mitomycin C infusion causes dose-limiting marrow toxicity. Recommended doses are 3 mg/m2/d for 5-day therapy and 0.75 mg/m2/d for protracted therapy to avoid toxicity.
Area of Science:
- Oncology
- Pharmacology
- Clinical Medicine
Background:
- Mitomycin C is an antineoplastic agent used in cancer treatment.
- Constant infusion delivery methods are being explored to optimize drug efficacy and safety.
- Understanding dose-limiting toxicities is crucial for safe mitomycin C administration.
Purpose of the Study:
- To evaluate the dose-limiting marrow toxicity of mitomycin C administered via constant infusion.
- To compare toxicity profiles between short-term (5-day) and protracted (9-30 day) infusion schedules.
- To determine recommended dose rates for safe and effective mitomycin C infusion therapy.
Main Methods:
- Thirty patients received mitomycin C via constant infusion.
- Two schedules were used: 5-day infusion (16 patients) and 9-30 day infusion (14 patients).
- Dose rates varied, with cumulative doses monitored for toxicity.
Main Results:
- Marrow suppression was dose-limiting in both schedules.
- Toxicity occurred above 30 mg cumulative dose in short-term and 20 mg in protracted infusions.
- Thrombocytopenia preceded or occurred without leukopenia, with delayed nadir days.
Conclusions:
- Constant infusion of mitomycin C leads to dose-limiting marrow toxicity at cumulative doses of 20-30 mg.
- Recommended dose rates are 3 mg/m2/d for 5-day therapy and 0.75 mg/m2/d for protracted therapy.
- Careful dose monitoring is essential to manage mitomycin C-induced myelosuppression.